Cancer
Conditions
Keywords
Cancer, Sunitinib, capecitabine, anastrozole, letrozole, adherence, anticancer treatment
Brief summary
The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a Medication Event Monitoring System (MEMS®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.
Interventions
OTHEREvaluation of adherence to 3 oral anticancer treatment using a Medication Event Monitoring System
Evaluation of adherence using a Medication Event Monitoring System (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy
Sponsors
Centre Jean Perrin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * histologically proven malignant tumor * documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor * ambulatory treated subject * Subject who accept to use MEMS monitors to automatically compile their drug dosing histories * Written informed consent
Exclusion criteria
* any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol * patient who does not agreed to participate the program
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. | everey visit during 6 months |
Secondary
| Measure | Time frame |
|---|---|
| evaluation of liberal nurse satisfaction | inclusion |
| resort to healthcare system (oncologist, doctor, nurse, hospital pharmacy, dispensary pharmacy) | during 6 months |
| Patient satisfaction | 6 months |
| drug interaction | during 6 months |
Countries
France
Outcome results
None listed